Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2097)	1/7/2008 12:37:22 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

MNKD Was up 18.4% earlier, but is up only 9.75% at present.<g> bigcharts.marketwatch.com It will be presenting tomorrow at the JPMorgan Health Care conference in Frisco. MNKD supposedly is developing products for diabetes & cancer. Its MKC1106-PP is a DNA vector with two synthetic peptides delivered via a plasmid prime-peptide boost treatment.It is in a PI designed to target two tumor-specific antigens, preferential antigen of melanoma (PRAME) and prostate specific membrane antigen (PSMA). The stock made an all time L on Friday. It trades around 1.0xBV with a negative CF of > $4.40 & a short ratio around 26x its ADV,in spite that it came down some in the last month.<g> Although MNKD has trimmed some its losses in the last 2Qs, it seems it will have a hard time going over its resistance above the $8.85 level.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2097)	1/14/2008 1:30:32 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

MRK opened with a DG today after it said that patients with high cholesterol fared no better when taking Vytorin than with a high dose of the generic form of Zocor. The stock is still down around 2.23% bigcharts.marketwatch.com The ENHANCE trial focused on a group of 720 patients with familial hypercholesterolemia. Patients were given either Vytorin or a high dose of Zocor. (Vytorin is a combination of SGP's Zetia & MRK's Zocor, which lost patent protection in 2006.) MRK & SGP have submitted an abstract on the ENHANCE trial for presentation at the ACC meeting, which will be held in March,& are still waiting notification of acceptance from the College. MRK's stock is still holding its present UT & hasn't closed its Apr13 UG bigcharts.marketwatch.com On Dec12 MRK was able to trade above its June 2003 H of $60.07 With some good news it may get to test its June 2001 at $71.76 The resistance from the Nov200 H at $91.47 & the Dec-Jan double top at $90.76 looks too far at present.<g> bigcharts.marketwatch.com Bernard